Literature DB >> 1318905

Antagonism of lipopolysaccharide-induced priming of human neutrophils by lipid A analogs.

A L Van Dervort1, M E Doerfler, P Stuetz, R L Danner.   

Abstract

Lipid X, a monosaccharide precursor of the lipid A component of LPS, has been found to antagonize LPS-induced priming of human neutrophils in a manner consistent with competitive inhibition. In this investigation, the inhibition of neutrophil priming by lipid A analogs was found to be specific for LPS-induced priming. Priming of neutrophils by TNF, IL-8, and C5a were all unaffected by increasing concentrations of 3-aza-lipid X-4-phosphate (compound 3), a monosaccharide LPS-antagonist. Unlike lipid X, the pattern of antagonism exhibited by some monosaccharide LPS-antagonists was noncompetitive-like. The relationship between the chemical structure and inhibition pattern was found to be complex and not simply related to the type of acyl linkage at the C-3 position of the glucosamine backbone. Lipid A analogs were found to antagonize calcium ionophore A23187-stimulated leukotriene B4 (LTB4) production from LPS-primed neutrophils in a pattern of inhibition qualitatively similar to that seen with FMLP-stimulated O2- production. Resting and FMLP-stimulated (peak) cytosolic-free calcium levels did not differ significantly between unprimed and LPS-primed neutrophils, (p = 0.67 and p = 0.97, respectively). Furthermore, antagonism of LPS-mediated priming by 3-aza-lipid X-4-phosphate (compound 3) could not be explained by changes in intracellular calcium flux despite marked inhibition of O2- production (p less than 0.0001). Thus, lipid A analogs antagonize only LPS-induced priming and the pattern of inhibition is dependent on the chemical structure. Inhibition of LPS-induced priming by lipid A analogs may involve an early step in the signal transduction pathway common to both O2- and LTB4 generation, but independent of intracellular calcium concentration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318905

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Modulation of CD14 and TLR4·MD-2 activities by a synthetic lipid A mimetic.

Authors:  Roberto Cighetti; Carlotta Ciaramelli; Stefania Enza Sestito; Ivan Zanoni; Łukasz Kubik; Ana Ardá-Freire; Valentina Calabrese; Francesca Granucci; Roman Jerala; Sonsoles Martín-Santamaría; Jesus Jiménez-Barbero; Francesco Peri
Journal:  Chembiochem       Date:  2013-12-12       Impact factor: 3.164

2.  Role of calcium during lipopolysaccharide stimulation of neutrophils.

Authors:  D A Rodeberg; G F Babcock
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Induction of early gene expression in murine macrophages by synthetic lipid A analogs with differing endotoxic potentials.

Authors:  P Y Perera; C L Manthey; P L Stütz; J Hildebrandt; S N Vogel
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

4.  Modulation of lipopolysaccharide-induced macrophage gene expression by Rhodobacter sphaeroides lipid A and SDZ 880.431.

Authors:  C L Manthey; P Y Perera; N Qureshi; P L Stütz; T A Hamilton; S N Vogel
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

5.  Modulation of lipopolysaccharide binding to human granulocytes.

Authors:  A J Weersink; K P Van Kessel; M E Van der Tol; J Verhoef
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

6.  A novel synthetic lipid A analog with low endotoxicity, DT-5461, prevents lethal endotoxemia.

Authors:  K Sato; Y C Yoo; A Fukushima; I Saiki; T A Takahashi; M Fujihara; S Tono-Oka; I Azuma
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

7.  Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages.

Authors:  C L Manthey; N Qureshi; P L Stütz; S N Vogel
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.